Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2018

View Archived Issues

Fixing nuclear transport helps cells cope with premature, normal aging

Combinations offer new antibiotic possibilities

Researchers find novel mutation in CLCC1 gene tied to retinitis pigmentosa

New rat model of diabetic cardiopathy described

Aeromics initiates phase I study of AER-271 in healthy volunteers

APC11 has prognostic significance in colorectal cancer

Renal anemia treatment: new oral HIF prolyl hydroxylase inhibitor promotes EPO production in rodents

New abzymes presented for diagnosing multiple sclerosis

Initiation of phase II clinical trial of BPN-14770 in fragile X syndrome

miRagen launches phase II study of MRG-201

Positive phase I results announced for Vivus' VI-0106

New NFE2L2 activators identified at GlaxoSmithKline

Aurigene Discovery Technologies patents BRD4 inhibitors

Janssen Pharmaceutica discovers new menin/MLL interaction inhibitors

Dihydroceramide desaturase inhibitors presented by Centaurus Therapeutics

Hitgen describes Rho-associated protein kinase inhibitors

Vidac begins phase IIb trial of VCA-1102 in actinic keratosis

Kamada receives scientific advice from EMA for phase III trial of inhaled AAT

First patient enrolled in phase II study of subcutaneous MABp1 in hidradenitis suppurativa

SRI and Ionis enter research agreement to explore combination of technologies

European Commission grants marketing approval to Verkazia for severe vernal keratoconjunctivitis

Scynexis releases phase IIb study data for SCY-078 in vulvovaginal candidiasis

Arbutus offers update on pipeline progress

PPCS gene mutations linked to dilated cardiomyopathy

Zynerba starts pivotal study of ZYN-002 gel in fragile X syndrome

[177Lu]EB-PSMA-617 shows promising safety and efficacy in patients with mCRPC

[11C]LSN-3172176 brain PET tracer shows potential for quantification of M1 receptor in humans

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...